Dr Esq - Enliven Therapeutics Chief Development
| ELVN Stock | 20.81 0.53 2.61% |
Executive
Dr Esq is Chief Development of Enliven Therapeutics
| Age | 47 |
| Address | 6200 Lookout Road, Boulder, CO, United States, 80301 |
| Phone | 720 647 8519 |
| Web | https://www.enliventherapeutics.com |
Enliven Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2187) % which means that it has lost $0.2187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3204) %, meaning that it created substantial loss on money invested by shareholders. Enliven Therapeutics' management efficiency ratios could be used to measure how well Enliven Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of March 2025, Return On Tangible Assets is likely to drop to -0.29. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Enliven Therapeutics' Total Assets are very stable compared to the past year. As of the 19th of March 2025, Total Current Assets is likely to grow to about 334 M, while Other Current Assets are likely to drop about 3.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Carolyn Trott | Replimune Group | N/A | |
| Lisa Nolan | Gossamer Bio | 63 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Neil CPA | Compass Therapeutics | 57 | |
| Brendan Eckelman | Inhibrx | 46 | |
| Minori MD | Compass Therapeutics | 62 | |
| David MBA | Inhibrx | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Emily Hill | Replimune Group | 45 | |
| MBA MA | Replimune Group | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Michael JD | Immuneering Corp | 38 | |
| Mario Orlando | Gossamer Bio | N/A | |
| MBA MD | Replimune Group | 58 | |
| Ronan JD | Lyra Therapeutics | 52 | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Barry JD | Compass Therapeutics | 53 | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Robert Richard | Lyra Therapeutics | 67 | |
| Robert Smith | Gossamer Bio | 56 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 |
Enliven Therapeutics Leadership Team
Elected by the shareholders, the Enliven Therapeutics' board of directors comprises two types of representatives: Enliven Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enliven. The board's role is to monitor Enliven Therapeutics' management team and ensure that shareholders' interests are well served. Enliven Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enliven Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Lyssikatos, CoFounder Officer | ||
| Anish PharmD, CoFounder COO | ||
| Helen MD, Chief Officer | ||
| Benjamin Hohl, CFO Development | ||
| Samuel MBA, CEO, CoFounder | ||
| Dr Esq, Chief Development |
Enliven Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enliven Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 739.3 M | ||||
| Shares Outstanding | 49 M | ||||
| Shares Owned By Insiders | 6.42 % | ||||
| Shares Owned By Institutions | 93.58 % | ||||
| Number Of Shares Shorted | 7.44 M | ||||
| Price To Book | 3.33 X | ||||
| EBITDA | (104.24 M) | ||||
| Net Income | (89.02 M) |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.